Incyte Corp Dossier - Source-backed chat

Incyte Corp

INCYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.84

Intrinsic Value $120.04median of 6 methods · middle span $103-$244based on filings through 31 Mar 2026

Market Price $117.14Price as of 1 Oct 2026

Near fair valueIntrinsic value is 2% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $23.7B

Enterprise Value $20.3B

Shares Outstanding 209.3M diluted

Moat Rating Wide

Next Earnings Date30 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

The operating outlook is constructive but event-dependent. Second-quarter 2026 net sales increased across the marketed portfolio, and management raised full-year total-net-sales, Opzelura, and Hematology and Oncology guidance. However, the headline quarter included a USD 246 million one-time, non-cash Opzelura benefit, making underlying demand growth more informative than reported growth. Ten clinical readouts expected during the second half of 2026 create meaningful upside opportunities but also concentrate clinical and regulatory risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets23 analysts · as of 18 Aug 2026

Low · most bearish analyst$86.00

Mean target$125.17

High · most bullish analyst$155.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$86.0020%

Underlying sales growth slows after the CMS-related benefit rolls out of comparisons, while delays or disappointing data reduce the value of the concentrated second-half catalyst slate. Weak commercialization of newer products or poor returns from acquired and internally developed programs would leave the growth profile more dependent on mature products.

Base CaseCentral scenario

$125.1755%

Matches the consensus mean

Incyte delivers within its raised 2026 sales ranges while Jakafi grows moderately and newer products provide increasing diversification. Clinical readouts are mixed but preserve several important late-stage opportunities.

Bull CaseUpside scenario

$155.0025%

Commercial execution remains broad-based, Opzelura sustains strong underlying demand, Hematology and Oncology growth products continue scaling, and a substantial majority of the planned second-half readouts support advancement or approval. Successful execution would strengthen evidence that the company can broaden growth beyond its established ruxolitinib franchise.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Broad commercial momentum: second-quarter 2026 net sales grew across marketed products, with management reporting 17% total-net-sales growth after excluding the one-time Opzelura benefit.
Raised 2026 guidance for total net sales, Opzelura, and the Hematology and Oncology portfolio indicates stronger commercial expectations than at the beginning of the quarter.
A dense catalyst slate includes ten expected second-half 2026 data readouts, four involving registrational trials, alongside potential approvals and launches.

Key Investment Risks

The USD 246 million one-time, non-cash Opzelura benefit materially inflated reported second-quarter growth, so headline comparisons overstate recurring commercial momentum.
The investment case depends on numerous clinical, regulatory, and launch events; unsuccessful trials, safety findings, review delays, or weak uptake could materially reduce expected pipeline value.
The Vega Therapeutics acquisition adds a Phase 3 asset but also creates integration, development, and capital-allocation risk before latarcibart's anticipated early-2029 topline data.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.